- Medco study: Half of women 40 years and older don’t get annual mammograms
- FDA approves Merck's Gardasil for prevention of anal cancer
- Adherence among chronic disease patients can lead to big savings
- FDA looks to pull the plug on Avastin's breast cancer indication
- Walgreens puts its money where its mouth is with World AIDS Day campaign
THOUSAND OAKS, Calif. — A drug made by Amgen was able to delay certain bone problems in patients with advanced breast cancer better than a competing drug, according to study results presented at the 33rd annual San Antonio Breast Cancer Symposium.
Amgen said Xgeva (denosumab) was able to delay weakness and fracturing resulting from the cancer spreading to the bones five months longer than Novartis’ Zometa (zoledronic acid).
The Food and Drug Administration approved Xgeva on Nov. 18.